AB0112 IT IS SAFE AND EFFECTIVE TO USE HUMAN CXCL5 TO TREAT MURINE LUPUS

Background As a novel myeloid/neutrophil-targeting therapy for systemic lupus erythematosus (SLE), the therapeutic efficacy of administering mouse ( m )CXCL5 to lupus-prone mice have been demonstrated by our group recently [1,2] . Objectives The aim this study is examine pre-clinical safety and establish pharmacokinetic (PK) response human h ease commercialization bring discovery from bench bedside. Methods Immediate accumulative liver kidney toxicity were determined alanine transaminase aspartate activity urinary albumin-to-creatinine ratio (ACR). CXCL5 expression in major internal organs (e.g., kidneys, lungs, liver, heart, brain spleen) was immunofluorescent staining on snap-frozen sections. Whether promoted cancer cell growth examined both vitro vivo renal carcinoma models. Haematological circulating immunity, counts white blood cells, red monocytes, neutrophils, T cells B evaluated Institute Cancer Research (ICR) healthy MRL/lpr (Fas lpr ) mice. PK performed ICR Fas intravenously. Results Our showed that it safe administer CXCL5. There no or inducing effects. further inflammation caused administration. Major components immune system also not compromised. endogenous levels altered exogenous administration mice, but increased Blood only detectable within 24 hours post-administration peak positively correlated with dosage. Mice survival improved reversely Conclusion It effective use treat murine lupus. References [1]Fan X, Ng CT, Guo D, et al. dampens improves via myeloid neutrophil pathways. Arthritis Rheumatol Oct 14 2022;doi:10.1002/art.42383 [2]Phillips R. model SLE. Nat Rev Dec 2022;18(12):673. doi:10.1038/s41584-022-00869-2 Acknowledgements: NIL. Disclosure Interests None Declared.